title: Vitrectomy After ocriplasmin for VitreOmacular adhesion Or Macular hole (VAVOOM) study.
abstract: OBJECTIVE
  To describe the results of pars plana vitrectomy (PPV) for persistent symptomatic vitreomacular traction (VMT) with or without macular hole (MH) after intravitreal ocriplasmin injection.
  
  
  METHODS
  Multicentre retrospective study of eyes that received intravitreal ocriplasmin between January 2013 and January 2014 for symptomatic VMT with or without MH, and then went on to PPV (ocriplasmin-treated group) for persistent pathology, compared with a control group of patients with symptomatic VMT with or without MH who were offered ocriplasmin injection but proceeded directly to PPV (PPV-only group). Intraoperative characteristics, visual acuity (VA) outcomes and spectral-domain optical coherence tomography images were reviewed for the two groups. Primary outcome measure was VA after PPV.
  
  
  RESULTS
  51 eyes of 51 patients underwent PPV after receiving ocriplasmin, and 22 eyes of 22 patients proceeded directly to PPV. Although VA was significantly better at all time points in the PPV-only compared with the ocriplasmin-treated group, at 3 and 6 months after PPV both groups had similar amount of visual improvement. Both groups had similar rates of pathology resolution; 50/51 (98%) eyes in the ocriplasmin group and 22/22 (100%) eyes in the PPV-only group had release of VMT and/or MH closure after PPV. The two groups had similar PPV-related complication rates.
  
  
  CONCLUSIONS
  Eyes with persistent symptomatic VMT and/or MH have similarly high rates of pathology resolution as well as similar VA gains regardless of whether they received ocriplasmin prior to PPV.
authors.affiliation: Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania, USA Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California, USA.
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Greven
authors.affiliation: Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania, USA.
authors.forename: Sunir
authors.initials: S
authors.lastname: Garg
authors.affiliation: Rutgers, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
authors.forename: Bing
authors.initials: B
authors.lastname: Chiu
authors.affiliation: Rutgers, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA NJ Retina, New Brunswick, New Jersey, USA.
authors.forename: Sumit P
authors.initials: SP
authors.lastname: Shah
authors.affiliation: Associated Retinal Consultants, Royal Oak, Michigan, USA.
authors.forename: Jeremy
authors.initials: J
authors.lastname: Wolfe
authors.affiliation: Rutgers, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA NJ Retina, New Brunswick, New Jersey, USA.
authors.forename: Howard F
authors.initials: HF
authors.lastname: Fine
authors.affiliation: Rutgers, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA NJ Retina, New Brunswick, New Jersey, USA.
authors.forename: Daniel B
authors.initials: DB
authors.lastname: Roth
authors.affiliation: Emory Eye Center, Atlanta, Georgia, USA.
authors.forename: Joshua
authors.initials: J
authors.lastname: Robinson
authors.affiliation: Eye Clinic of Wyandotte, Wyandotte, Michigan, USA.
authors.forename: Jacob
authors.initials: J
authors.lastname: Mong
authors.affiliation: Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania, USA.
authors.forename: Jason
authors.initials: J
authors.lastname: Hsu
authors.affiliation: Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania, USA.
authors.forename: Carl
authors.initials: C
authors.lastname: Regillo
authors.affiliation: Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania, USA.
authors.forename: Allen
authors.initials: A
authors.lastname: Ho
authors.affiliation: Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania, USA.
authors.forename: Julia A
authors.initials: JA
authors.lastname: Haller
mesh_terms: D000368:Aged; D005260:Female; D005341:Fibrinolysin / Q000008:administration & dosage / Q000009:adverse effects*; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D010446:Peptide Fragments / Q000008:administration & dosage / Q000009:adverse effects*; D012160:Retina / Q000000981:diagnostic imaging*; D012167:Retinal Perforations / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery*; D012189:Retrospective Studies; D013997:Time Factors; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity; D014821:Vitrectomy / Q000379:methods*
chemical_list: D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin
keywords: Macula; Retina; Vitreous